+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Thyroid Cancer Drugs Market by Drug (Cabozantinib-S-Malate, Caprelsa, Cometriq), End User (Hospitals, Oncology Clinics, Research Organizations) - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5460329
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Thyroid Cancer Drugs Market size was estimated at USD 685.14 million in 2023, USD 756.79 million in 2024, and is expected to grow at a CAGR of 10.55% to reach USD 1,382.70 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Thyroid Cancer Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Thyroid Cancer Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Thyroid Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Biovista Inc., Bristol Myers Squibb, Eisai Co., Ltd., Eli Lilly and Company, Exelixis Inc., GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc, Mylan N.V., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd, and Vascular Biogenics Ltd.

Market Segmentation & Coverage

This research report categorizes the Thyroid Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Cabozantinib-S-Malate
    • Caprelsa
    • Cometriq
    • Doxorubicin Hydrochloride
    • Ipilimumab
    • Lenvatinib Mesylate
    • Nivolumab
    • Vandetanib
  • End User
    • Hospitals
    • Oncology Clinics
    • Research Organizations
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Thyroid Cancer Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Thyroid Cancer Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Thyroid Cancer Drugs Market?
  4. What is the market share of the leading vendors in the Thyroid Cancer Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Thyroid Cancer Drugs Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Thyroid Cancer Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of thyroid cancer cases across the globe
5.1.1.2. Increasing focus on early diagnosis and treatment
5.1.1.3. Private organizations increasing cancer screening programs
5.1.2. Restraints
5.1.2.1. Dearth of skilled workers and standardization of the procedure
5.1.3. Opportunities
5.1.3.1. Favorable government initiatives promoting cancer awareness and introduction of reimbursement policies
5.1.3.2. Ongoing advancements in treatment procedures with improved quality
5.1.4. Challenges
5.1.4.1. Stringent government drug approval procedures
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Thyroid Cancer Drugs Market, by Drug
6.1. Introduction
6.2. Cabozantinib-S-Malate
6.3. Caprelsa
6.4. Cometriq
6.5. Doxorubicin Hydrochloride
6.6. Ipilimumab
6.7. Lenvatinib Mesylate
6.8. Nivolumab
6.9. Vandetanib
7. Thyroid Cancer Drugs Market, by End User
7.1. Introduction
7.2. Hospitals
7.3. Oncology Clinics
7.4. Research Organizations
8. Americas Thyroid Cancer Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Thyroid Cancer Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Thyroid Cancer Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AstraZeneca PLC
12.1.2. Bayer AG
12.1.3. Biovista Inc.
12.1.4. Bristol Myers Squibb
12.1.5. Eisai Co., Ltd.
12.1.6. Eli Lilly and Company
12.1.7. Exelixis Inc.
12.1.8. GlaxoSmithKline PLC
12.1.9. Lupin Limited
12.1.10. Merck & Co., Inc
12.1.11. Mylan N.V.
12.1.12. Novartis AG
12.1.13. Sanofi S.A.
12.1.14. Teva Pharmaceutical Industries Ltd
12.1.15. Vascular Biogenics Ltd.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. THYROID CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. THYROID CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. THYROID CANCER DRUGS MARKET DYNAMICS
FIGURE 7. THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 8. THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 6. THYROID CANCER DRUGS MARKET SIZE, BY CABOZANTINIB-S-MALATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. THYROID CANCER DRUGS MARKET SIZE, BY CAPRELSA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. THYROID CANCER DRUGS MARKET SIZE, BY COMETRIQ, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. THYROID CANCER DRUGS MARKET SIZE, BY DOXORUBICIN HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. THYROID CANCER DRUGS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. THYROID CANCER DRUGS MARKET SIZE, BY LENVATINIB MESYLATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. THYROID CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. THYROID CANCER DRUGS MARKET SIZE, BY VANDETANIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 15. THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. CANADA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 26. CANADA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 28. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 33. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 36. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. CHINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 38. CHINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. INDIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 40. INDIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 42. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 44. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 46. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 48. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 50. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 52. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 54. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 56. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 58. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 63. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 65. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 67. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 69. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 71. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 73. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. ITALY THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 75. ITALY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 77. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 79. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 81. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. POLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 83. POLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. QATAR THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 85. QATAR THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 87. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 89. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 91. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 93. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 95. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 97. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 99. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 101. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 105. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 106. THYROID CANCER DRUGS MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca PLC
  • Bayer AG
  • Biovista Inc.
  • Bristol Myers Squibb
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis Inc.
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc
  • Mylan N.V.
  • Novartis AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd
  • Vascular Biogenics Ltd.

Methodology

Loading
LOADING...

Table Information